<DOC>
	<DOCNO>NCT02488382</DOCNO>
	<brief_summary>The aim study evaluate efficacy tolerability Lonquek pegylated ( long-acting ) version Filgrastim recombinant human G-CSF ( G-CSF ) mobilize sufficient number stem cell autologous stem cell transplantation patient lymphoma multiple myeloma .</brief_summary>
	<brief_title>Lonquek Autologous Stem Cell Mobilization</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Patients confirm multiple myeloma Hodgkins non Hodgkin lymphoma need autologous stem cell transplantation . Disease must chemosensitive stable status prior therapy transplant . Age 18 65 year inclusive . ECOG performance status 0 , 1 2 . Written informed consent . Adequate birth control fertile patient . Lymphoma patient fulfill inclusion criterion . Patients factor predict poor mobilization include &gt; 3 line previous chemotherapy , extensive irradiation , patient receive stem cell toxicity drug like Melphalan , Fludarabine , &gt; 2 course Revlimid , age &gt; 65 year , platelets count &lt; 100x109/L , WBC &lt; 2.5x109/L WBC &gt; 35x109/L . Previous autologous stem cell transplantation . Inability tolerate peripheral blood stem cell harvest . Peripheral venous access possible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>stem cell mobilization</keyword>
	<keyword>autologous stem cell transplantation</keyword>
</DOC>